Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.04
  • Today's Change0.06 / 6.15%
  • Shares traded6.42m
  • 1 Year change+183.55%
  • Beta2.9155
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Mesoblast Ltd have a median target of 1.39, with a high estimate of 2.55 and a low estimate of 1.07. The median estimate represents a 34.69% increase from the last price of 1.04.
High146.7%2.55
Med34.7%1.39
Low3.5%1.07

Earnings history & estimates in USD

On Aug 30, 2023, losses of -0.027 per share. This result exceeded the -0.12 consensus loss of the 4 analysts covering the company
Average growth rate+0.28%
Mesoblast Ltd reported annual 2024 losses of -0.089 per share on Aug 28, 2024.
Average growth rate+9.73%
More ▼

Revenue history & estimates in USD

of 2.14m. This missed the 3.33m consensus estimate of the 4 analysts following the company.
Average growth rate+2.67%
Mesoblast Limited had revenues for the full year 2024 of 5.90m. This was 21.32% below the prior year's results.
Average growth rate-21.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.